Eli Lilly and Co. halted development of an Alzheimer’s drug after it worsened patients’ symptoms in late-stage studies, dealing a fresh blow to the U.S. drugmaker and to research to fight the disease.
The Alzheimer’s setback comes as U.S. regulators raised concerns about using Lilly’s antidepressant Cymbalta to treat chronic pain and follows patent case losses on two other key products in the last month. Get the full story »
